Serum and Urinary sCD163 in IgA Nephropathy
Running, not enrolling
Conditions studied: IgA Nephropathy
In brief
IgA nephropathy is a common primary glomerular disease with a highly variable clinical course. Soluble CD163 is a marker associated with monocyte and macrophage activation and may reflect inflammatory activity in kidney disease. This single-center observational study aims to evaluate the associations of serum and urinary soluble CD163 levels with clinical disease activity, histopathologic severity, and renal prognosis in patients with IgA nephropathy. Clinical, laboratory, and kidney biopsy findings will be assessed together with serum and urinary soluble CD163 measurements. Participants will also be followed for renal outcomes, including changes in kidney function and proteinuria. The study is expected to clarify whether soluble CD163 may serve as a noninvasive biomarker of disease activity and prognosis in IgA nephropathy.
Key facts
- Study ID
- NCT07754019
- Run by
- Bezmialem Vakif University
- People needed
- 87
- Starts
- 2025-02-03
- Expected to finish
- 2026-09-01
- Last updated by the study team
- 2026-08-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- - Age 18 years or older
- Biopsy-proven primary IgA nephropathy or primary focal segmental glomerulosclerosis
- Stable kidney function with an estimated glomerular filtration rate greater than 30 mL/min/1.73 m²
- Availability of serum and urine samples for soluble CD163 measurement
- Availability of relevant demographic, clinical, laboratory, histopathologic, and follow-up data
- For the healthy control group: age- and sex-matched individuals without known chronic disease and with normal kidney function
- Written informed consent
You may not qualify if…
- - Secondary IgA nephropathy or secondary focal segmental glomerulosclerosis
- Active infection
- Acute kidney injury
- End-stage kidney disease or ongoing dialysis treatment
- Estimated glomerular filtration rate below 15 mL/min/1.73 m²
- Recent use of corticosteroids or immunosuppressive therapy
- Pregnancy
- Active malignancy or history of malignancy
- Inadequately stored or unavailable serum and/or urine samples
- Missing essential clinical, laboratory, histopathologic, or follow-up data
- Absence of written informed consent
Where it is running
- Bezmialem Vakif University Health Application and Research Center — Istanbul, Turkey (Türkiye)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.